ChemoCentryx Inc. (CCXI)’s Financial Results Comparing With OHR Pharmaceutical Inc. (NASDAQ:OHRP)

ChemoCentryx Inc. (NASDAQ:CCXI) and OHR Pharmaceutical Inc. (NASDAQ:OHRP) are two firms in the Biotechnology that compete against each other. Below is a comparison of their profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ChemoCentryx Inc. 89.84M 6.16 12.47M 0.19 52.02
OHR Pharmaceutical Inc. N/A 0.00 9.98M -0.22 0.00

Table 1 demonstrates ChemoCentryx Inc. and OHR Pharmaceutical Inc.’s top-line revenue, earnings per share and valuation.


Table 2 hightlights the net margins, return on assets and return on equity of the two companies.

Net Margins Return on Equity Return on Assets
ChemoCentryx Inc. 13.88% 32.2% 6.5%
OHR Pharmaceutical Inc. 0.00% -62.7% -54.6%

Volatility & Risk

ChemoCentryx Inc.’s 1.72 beta indicates that its volatility is 72.00% more volatile than that of S&P 500. OHR Pharmaceutical Inc.’s 103.00% less volatile than S&P 500 volatility due to the stock’s -0.03 beta.


The Current Ratio and a Quick Ratio of ChemoCentryx Inc. are 2.9 and 2.9. Competitively, OHR Pharmaceutical Inc. has 5.5 and 5.5 for Current and Quick Ratio. OHR Pharmaceutical Inc.’s better ability to pay short and long-term obligations than ChemoCentryx Inc.

Analyst Ratings

The next table highlights the delivered recommendations and ratings for ChemoCentryx Inc. and OHR Pharmaceutical Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
ChemoCentryx Inc. 0 1 3 2.75
OHR Pharmaceutical Inc. 0 0 0 0.00

ChemoCentryx Inc.’s consensus target price is $17.5, while its potential upside is 59.67%.

Institutional & Insider Ownership

The shares of both ChemoCentryx Inc. and OHR Pharmaceutical Inc. are owned by institutional investors at 55.5% and 14.6% respectively. About 4.8% of ChemoCentryx Inc.’s share are held by insiders. Insiders Comparatively, held 8.91% of OHR Pharmaceutical Inc. shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
ChemoCentryx Inc. -0.1% -16.33% -9.75% -15.2% 69.59% 68.74%
OHR Pharmaceutical Inc. -5.33% -32.38% -25.58% -34.41% -90.21% -92.37%

For the past year ChemoCentryx Inc. had bullish trend while OHR Pharmaceutical Inc. had bearish trend.


On 10 of the 11 factors ChemoCentryx Inc. beats OHR Pharmaceutical Inc.

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan (CCX168), an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). The company also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe CrohnÂ’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis. It has a partnership with Vifor (International) Ltd. for the geographic commercial rights of Avacopan in Europe and other international markets. ChemoCentryx, Inc. was founded in 1997 and is headquartered in Mountain View, California.

OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes. The company is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion. Its preclinical pipeline of sustained release programs include sustained release formulations of small molecule and protein therapeutics for the treatment of ocular diseases, such as glaucoma, steroid induced glaucoma, ocular allergy, and retinal disease. OHR Pharmaceutical, Inc. is headquartered in New York, New York.


Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.